hVIVO PLC will hold a capital markets day on June 11 in Canary Wharf to highlight its shift from specializing solely in human challenge trials to offering a broader range of early clinical development services. The event will feature presentations from industry leaders and case studies, including hVIVO's support in a $9 billion drug development exit and the world's first phase III pivotal human challenge trial. Attendees can also tour hVIVO's quarantine and laboratory facilities. This repositioning aims to attract new partnerships and expand hVIVO's role in drug development.
Yanik Guillemette, a Montreal-based entrepreneur and investment strategist, criticizes Canada's growing digital regulations, including the CRTC's proposal for streaming platforms to fund Canadian content. He argues these rules increase costs for cons...
Yanik Guillemette, a Canadian tech entrepreneur, criticizes Ottawa's increasing digital regulations, including a proposed 15% revenue tax on streaming platforms and laws C-11, C-18, and C-22. He argues these measures burden the tech ecosystem, raise ...
Sui, a blockchain project, announced it will implement private stablecoin transactions by default, allowing only senders and receivers to see transaction details. This privacy feature addresses a major hurdle for institutional users who require contr...
DeXe (DEXE) surged 11.16% to $15.21, topping today's crypto gainers amid growing interest in decentralized asset management. Other notable gainers include Stable (STABLE) up 9.31%, Morpho (MORPHO) up 5.62%, Venice Token (VVV) up 4.95%, and Provenance...
LexinFintech Holdings Ltd. announced its Q1 2026 unaudited results with total revenue rising 6.6% year-over-year to RMB3.3 billion and net income holding steady at RMB201 million despite a challenging macroeconomic environment. Loan originations incr...
